» Articles » PMID: 25698082

Activated Mutant P110α Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2015 Feb 21
PMID 25698082
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

PTEN and PIK3CA mutations occur with high frequency in uterine endometrioid carcinoma (UEC). Although PTEN mutations are present in complex atypical hyperplasia and carcinoma, PIK3CA mutations are restricted to carcinoma. We generated mouse models harboring Pten loss and/or activated Pik3ca in the endometrial epithelium to investigate their respective roles in the pathogenesis of UEC. Presence of an activated mutant Pik3ca on the background of Pten loss led to aggressive disease, with 100% of mice exhibiting carcinoma. Expression of Pik3ca with E545K mutation alone was unable to cause hyperplasia or cancer in the uterus and did not activate Akt as effectively as Pten deletion in short-term cultures of mouse endometrial epithelium, likely explaining the lack of phenotype in vivo. We also report that nuclear localization of FOXO1 correlated with PTEN mutational status irrespective of the PIK3CA status in endometrial cancer cell lines. Furthermore, gene expression profiles resulting from Pten loss or activation of Pik3ca in primary mouse endometrial epithelial cells exhibit minimal overlap. Thus, Pten and Pik3ca have distinct consequences on the activation of the phosphatidylinositol 3-kinase pathway in endometrial epithelium and are likely to affect other nonoverlapping cellular mechanisms involved in the development and progression of the most common type of uterine cancer.

Citing Articles

Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs.

Ren F, Wang L, Wang Y, Wang J, Wang Y, Song X Cell Death Dis. 2024; 15(8):571.

PMID: 39112478 PMC: 11306564. DOI: 10.1038/s41419-024-06960-8.


Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells.

Zhao J, Du X, Si W, Zhao X, Zhou Z Histol Histopathol. 2024; 39(9):1197-1208.

PMID: 38318760 DOI: 10.14670/HH-18-711.


Comparison of clinical characteristics and prognosis between type I and type II endometrial cancer: a single-center retrospective study.

Wang Y, Sun Y, Sun F, Han P, Fan R, Ren F Discov Oncol. 2023; 14(1):211.

PMID: 37994955 PMC: 10667178. DOI: 10.1007/s12672-023-00820-1.


ENDOMETRIAL CARCINOMA: THE INTERPLAY OF GENETICS AND HORMONES.

Ellenson L Trans Am Clin Climatol Assoc. 2023; 133:274-282.

PMID: 37701602 PMC: 10493730.


Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.

Ocasio J, Budd K, Roach J, Andrews J, Baker S Cancer Metastasis Rev. 2023; 42(2):367-388.

PMID: 37119408 PMC: 10441521. DOI: 10.1007/s10555-023-10105-2.


References
1.
Di Cristofano A, Ellenson L . Endometrial carcinoma. Annu Rev Pathol. 2007; 2:57-85. DOI: 10.1146/annurev.pathol.2.010506.091905. View

2.
Buzzio O, Lu Z, Miller C, Unterman T, Kim J . FOXO1A differentially regulates genes of decidualization. Endocrinology. 2006; 147(8):3870-6. DOI: 10.1210/en.2006-0167. View

3.
Kajihara T, Jones M, Fusi L, Takano M, Feroze-Zaidi F, Pirianov G . Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol. 2006; 20(10):2444-55. DOI: 10.1210/me.2006-0118. View

4.
Goto T, Takano M, Albergaria A, Briese J, Pomeranz K, Cloke B . Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. 2007; 27(1):9-19. DOI: 10.1038/sj.onc.1210626. View

5.
Ward E, Hoekstra A, Blok L, Hanifi-Moghaddam P, Lurain J, Singh D . The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology. 2007; 149(4):1942-50. PMC: 2276720. DOI: 10.1210/en.2007-0756. View